Vesely J J, Pien F D, Pien B C
Department of Medicine, University of Hawaii, John Burns School of Medicine, and Straub Clinic and Hospital, Honolulu, USA.
Pharmacotherapy. 1998 Mar-Apr;18(2):345-57.
Rifampin has clinical efficacy against a wide variety of organisms, including Staphylococcus aureus, Legionella pneumophila, group A Streptococcus, Brucella sp, Haemophilus influenzae, and Neisseria meningitidis, as well as in vitro activity against penicillin-resistant Streptococcus pneumoniae, Neisseria gonorrhoeae, Chlamydia trachomatis, Haemophilus ducreyi, and many gram-negative rods. Rifampin is a useful drug for several types of bacterial infections because of its broad spectrum of activity, excellent tissue penetration, and low side effect profile. In combination with other antibiotics, it may be effective when conventional therapies are not.
利福平对多种微生物具有临床疗效，包括金黄色葡萄球菌、嗜肺军团菌、A组链球菌、布鲁氏菌属、流感嗜血杆菌和脑膜炎奈瑟菌，以及对耐青霉素肺炎链球菌、淋病奈瑟菌、沙眼衣原体、杜克雷嗜血杆菌和许多革兰氏阴性杆菌具有体外活性。由于其广泛的活性谱、出色的组织穿透力和低副作用，利福平是治疗几种细菌感染的有用药物。与其他抗生素联合使用时，在传统疗法无效的情况下可能有效。
